Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus fulvestrant versus fulvestrant in ER-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor therapy
2017-005118-74Phase 2Unknown
- Sponsor
- Roche
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Venetoclax + fulvestrant with Fulvestrant (2 arms). Primary endpoint: Clinical benefit. Status: unknown.
02
Drugs
venetoclaxfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-005118-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005118-74.